Studies on Synthesis, Characterization, DNA Binding and Biological Activities of Two Trans-Planaramineplatinum(II) Complexes of the form PtL2R2 where L = 3-hydroxy Pyridine and R= Acetate Ligand


  • Fehmida Fasim Discipline of Biomedical Science, Sydney Medical School, The University of Sydney, Cumberland Campus C42, 75 East Street, Lidcombe, NSW 1825, Australia
  • Philip Beale Sydney Cancer Centre, Concord Hospital, Sydney, NSW 2139, Australia
  • Jun Qing Yu Discipline of Biomedical Science, Sydney Medical School, The University of Sydney, Cumberland Campus C42, 75 East Street, Lidcombe, NSW 1825, Australia
  • Fazlul Huq Discipline of Biomedical Science, Sydney Medical School, The University of Sydney, Cumberland Campus C42, 75 East Street, Lidcombe, NSW 1825, Australia



trans-platinums, drug design, steric hindrance, DNA binding, apoptosis.


The present study deals with the synthesis and characterization of trans-platinum(II) complexes of general formula trans-[PtL2(R)2], where L is 3-hydroxy pyridine and R is acetate ligand. The new complexes contain acetate ligands trans to the planaramine group 3-hydroxypyridine. The complexes were characterised by a combination of elemental analysis, IR, mass spectrum and 1H NMR spectroscopy. The increasing prevention of BamH1 digestion of form I and form II pBR322 plasmid DNA with the increase in concentration of the compound is believed to be due to interstrand binding that brings about global changes in DNA conformation. Acetate complexes' activity against human ovarian cancer cell lines: A2780, A2780cisR have also been determined. The complexes show a reduced reactivity, and decrease in cytotoxic activity compared to their chloro-counterparts. Further, the complexes are better able to overcome cisplatin resistance; they therefore present an interesting class of antitumour active trans-platinum acetate complexes.


Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 1996; 35(31): 10004-13.

Radulovic S, Tesic Z, Manic S. Trans-platinum complexes as anticancer drugs: Recent developments and future prospects. Curr Med Chem 2002; 9(17): 1611-18.

Kasparkva J, Novakova O, Marini V, Najajreh Y, Gibson D, Perez JM, Brabec V. Activation of trans geometry in bifunctional mononuclear platinum complexes by a piperidine ligand: Mechanistic studies on antitumor action. J Biol Chem 2003; 278(48): 47516-525.

Ma ESF, Bates WD, Edmunds A, Kelland LR, Fojo T, Farrell N. Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile. J Med Chem 2005; 48(18): 5651-54.

Quintal SMO, Qu Y, Quiroga AG, Moniodis J, Nogueira HIS, Farrell N. Pyridine-carboxylate complexes of platinum. Effect of N,O-chelate formation on model bifunctional DNA DNA and DNA Protein interactions. Inorg Chem 2005; 44: 5247- 54.

Kelland LR, Clarke SJ, McKeage MJ. Adances in platinum complex cancer chemotherapy. Platinum Metal Rev 1992; 36(4): 178-82.

Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McEIwain TJ, et al. Early clinical studies with cis-diammine1,1 -cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982; 9: 140-45.

Chowdhury MA, Huq F, Abdullah A, Beale P, Fisher K. Synthesis, characterization and binding with DNA of four planaramineplatinum(II) complexes of the forms: transPtL2Cl2 and

[PtL3Cl]Cl, where L = 3-hydroxypyridine, 4- hydroxypyridine and imidazo(1,2-alpha)pyridine. J Inorg Biochem 2005; 99(5): 1098-12.

Silverstein RM, Bassler GC, Morrill TC. Spectrometric identification of organic compounds. Wiley and Sons, New York 1991.

Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006; 12(9): 440-50.

Zhu WZ, Lin QY, Lu M, Hu RD, Zheng XL, Cheng JP, et al. Synthesis, characterization, DNA-binding and antiproliferative activity of Nd(III) complexes with N-(nitrogen heterocyclic) norcantharidin acylamide acid. J Fluorence 2009; 5: 857-66.

Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J. Adducts of the antitumor drug cisdiamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 1985; 24(3): 707-13.

Bedford P, Fichtinger-Schepman AM, Shellard SA, Walker MC, Masters JR, Hill BT. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 1988; 48(11): 3019-24.

Johnson SW, Ferry KV, Hamilton TC. Recent insights into platinum drug resistance in cancer. Drug Resistance Updates 1998; 1(4): 243-54.

Ho YP, Au-Yeung SC, To KK. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev 2003; 23: 633-55.

Boccarelli A, Coluccia M, Intini FP, Natile G, Locker D, Leng M. Cytotoxicity and DNA binding mode of new platinumiminoether derivatives with different configuration at the iminoether ligands. Anti-Cancer Drug Design 1999; 14(3): 253-64.

Huq F, Abdullah A, Chowdhury A, Cheng H, Tayyem H, Beale P. Studies on the synthesis and characterization, binding with DNA and activity of cis-bis{imidazo(1,2- a)pyridine}dichloroplatinum(II). Asian J Chem 2006; 18(3): 1637-48.

Stellawagen N. DNA gel electrophoresis. Nucleic acid electrophoresis, Springer, New York 1988; pp. 1-53.

Mosmannn TJ. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65(1-2): 55-63.

Farhad M, Yu JQ, Beale P, Fisher K, Huq F. Studies on the synthesis and activity of three tripalladium complexes containing planaramine ligands. ChemMedChem 2009; 4: 1841-49.

Bowtell DD. Rapid isolation of eukaryotic DNA. Anal Biochem 1987; 162: 463-65.